| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Medical Equipment/Supplies/Accessories
|
Compare with Industry peers |
| Website | http://www.prevestdenpro.com | |
| Market Cap | 377.37 Cr. | |
| Enterprise Value(EV) | 380.66 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 9.64 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 32.62 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 39.51 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 47.58 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 6.61 | Calculated using Price: 314.40 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.20 Cr. | 12,003,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
The company develops, manufacture and market a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. The breadth and depth of its product offerings address majority of the dentists’ clinical needs for consumable dental materials. Its product portfolio covers a wide spectrum of materials for endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and laboratory consumables. Its products are sold in the regions of Europe, Asia, South America, Middle East and Africa. Further, as per its diversification plans, the company is currently expanding its existing manufacturing unit by setting up another manufacturing facility for manufacturing new line of products that will include hygiene products (sanitizers and disinfectants), oral hygiene products (mouth washes and mouth rinses), oral care products(medicated ointments, gels and creams for dental treatment) and biomaterials (i.e. bone augmentation materials). The proposed facility will be well-equipped with latest machineries. Business area of the company The company manufactures and markets a range of dental materials for diagnosing, treating, and preventing dental conditions and improving the aesthetics of the human smile. Key events and milestones
|
||
Company Profile
The company develops, manufacture and market a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. The breadth and depth of its product offerings address majority of the dentists’ clinical needs for consumable dental materials. Its product portfolio covers a wide spectrum of materials for endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and laboratory consumables. Its products are sold in the regions of Europe, Asia, South America, Middle East and Africa. Further, as per its diversification plans, the company is currently expanding its existing manufacturing unit by setting up another manufacturing facility for manufacturing new line of products that will include hygiene products (sanitizers and disinfectants), oral hygiene products (mouth washes and mouth rinses), oral care products(medicated ointments, gels and creams for dental treatment) and biomaterials (i.e. bone augmentation materials). The proposed facility will be well-equipped with latest machineries.
Business area of the company
The company manufactures and markets a range of dental materials for diagnosing, treating, and preventing dental conditions and improving the aesthetics of the human smile.
Key events and milestones
| 1 Day |
|
-3.44% |
| 1 Week |
|
-12.72% |
| 1 Month |
|
-16.40% |
| 3 Month |
|
-6.23% |
| 6 Month |
|
+35.62% |
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 4 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 29.72 | 34.02 | 39.13 | 39.10 | |
| Return on Capital Employed (%) | 37.15 | 39.27 | 45.63 | 46.80 | |
| Return on Assets (%) | 18.88 | 22.30 | 27.50 | 28.74 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 7 | 10 | 15 | 23 | 57 | |
| Non Curr. Liab. | 1 | 2 | 2 | 2 | 2 | |
| Curr. Liab. | 3 | 3 | 4 | 6 | 5 | |
| Minority Int. | ||||||
| Equity & Liab. | 12 | 15 | 21 | 31 | 64 | |
| Non Curr. Assets | 4 | 5 | 6 | 7 | 11 | |
| Curr. Assets | 7 | 10 | 16 | 24 | 53 | |
| Misc. Exp. not W/O | ||||||
| Total Assets | 12 | 15 | 21 | 31 | 64 |
| Particulars | 4 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 17 | 19 | 23 | 27 | |
| Other Income | 1 | 0 | 2 | 2 | |
| Total Income | 18 | 20 | 25 | 30 | |
| Total Expenditure | -14 | -15 | -18 | -19 | |
| PBIDT | 4 | 4 | 7 | 10 | |
| Interest | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | |
| Taxation | -1 | -1 | -1 | -2 | |
| Exceptional Items | |||||
| PAT | 2 | 3 | 5 | 7 | |
| Adjusted EPS | 76 | 105 | 176 | 261 |
| Particulars | 4 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 2 | 3 | 5 | 9 | |
| Cash Fr. Inv. | -1 | -1 | -1 | -2 | |
| Cash Fr. Finan. | 0 | 0 | 0 | -1 | |
| Net Change | 1 | 2 | 4 | 6 | |
| Cash & Cash Eqvt | 4 | 6 | 10 | 16 |
|
Mon, 23 May 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the transcript of the aforesaid Conference Call held on May 19 2022 at 4 PM. |
|
Fri, 20 May 2022
Intimation Of Audio Recording Of Investor Call For HY2 FY 22 AND FY 22 Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 read along with SEBI (Listing Obligation & Disclosure Requirements) (Second Amendment) Regulations 2021 please find audio recording of the Companys Earning Call held with the Investors/ Analysis on May 19 2022 to discuss Audited Financial Results of the Company for the half year and year ended March 31 2022. |
|
Wed, 18 May 2022
Proceedings Of The Board Meeting Held On 17Thmay 2022 Pursuantto the Regulation 30 and 33 read with schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 we would like to inform you that the Board of Directors at its meeting held on Tuesday 17thMay 2022 inter-alia approved 1) Audited Financial Results for the Half Yearand Yearended on 31st March 2022along with Statement of Assets and Liabilities and Cash Flow Statement (Copy enclosed). 2) Auditors Report on the Audited Financial Results for the Half Year and Year ended on 31st March 2022 (Copy enclosed). |
| Tue, 24 May 2022 |
Closing Below Previous Low
|
High Decrease 1 Month
|
High Increase 6 Months
|
| Mon, 23 May 2022 |
High Delivery Percentage
|
Opening at High
|
Equities
M.F.
Sectors